Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) When Placed Within the Lower Eye Lid Canaliculus or Both the Upper and Lower Canaliculi for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.
Latest Information Update: 04 Jul 2023
At a glance
- Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Prednisone
- Indications Inflammation; Ocular pain; Retinal oedema
- Focus Therapeutic Use
Most Recent Events
- 27 Jun 2023 Planned End Date changed from 28 Feb 2022 to 31 Dec 2024.
- 27 Jun 2023 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2024.
- 27 Jun 2023 Status changed from not yet recruiting to recruiting.